Jiang Wei, Global Executive Vice President Of Bayer Prescription Medicine: China'S Pharmaceutical Industry Will Usher In A Golden Age And Full Confidence In China'S Economic Prospects.

Affected by the new crown virus epidemic, the medical and health industry has attracted much attention. Whether it is "effective drugs" clinical trials or vaccine research and development, every step affects everyone's heart. For this reason, Jiang Wei, global executive vice president of Bayer Group's pharmaceutical industry and President of China and Asia Pacific region and President of the Greater China region of Bayer Group, accepted an exclusive interview with the twenty-first Century economic news reporter that the new crown pneumonia epidemic will accelerate the construction and improvement of China's public health system, and will also promote the development of China's pharmaceutical industry.

Jiang Wei said: "with the continuous growth of innovative products and the dual promotion of original research products, a large number of Chinese pharmaceutical enterprises have become an important driving force for the development, and promote the development of the pharmaceutical industry. The next ten years will be the golden age for the development of China's pharmaceutical industry.

Despite the fact that China's economy has been in a "lockout" at the beginning of the year, the situation of epidemic prevention and control has continued to improve, and economic and social life has gradually returned to normal. The signals conveyed during the two sessions once again showed the good development of China's economy and China's determination to expand its opening up firmly.

Jiang Wei said that this year's government work report reflects that the government has always placed the economy, people's livelihood and the health and well-being of the masses in the first place. This has encouraged foreign enterprises rooted in China's development.

China's pharmaceutical industry will usher in a golden age

Twenty-first Century: what are the characteristics and trends of the development of China's pharmaceutical industry? For multinational pharmaceutical companies, how to deal with them?

Jiang Wei: since the reform and opening up, China's pharmaceutical industry has continued to upgrade and develop, and gradually realize the transformation from "made in China" to "created in China". Over the past 20 years, Bayer has witnessed and devoted himself to the development of China's medical and health development. He has insisted on doing "the right thing" and made contributions to the health of the Chinese people and the development of China's pharmaceutical industry.

Innovation is the foundation of the pharmaceutical industry. Only by persisting in innovation can we bring a valuable treatment plan to the patients. Since the invention of aspirin more than 120 years ago, Bayer has incorporated innovation into its own genes, becoming our core competitiveness and driving force.

With the continuous growth of innovative products and the dual promotion of original research products, a large number of Chinese pharmaceutical enterprises have become an important driving force for the development of the pharmaceutical industry. At present, China has become one of the hottest areas of global pharmaceutical innovation, and also an important promoter of future innovation.

The next ten years will be the golden age for the development of China's pharmaceutical industry. Bayer will also seize this opportunity to make full use of its advantages and cooperation with China's pharmaceutical industry to make more efforts to achieve the "healthy China 2030" strategy.

Twenty-first Century: every time the epidemic happens, pharmaceutical companies are highly regarded. How can we guarantee the continuous growth of R & D and innovation products for emergencies such as Bayer, in order to deal with emergencies and help solve some of the major challenges faced by today's human society?

Jiang Wei: innovative products are the core, but innovative products themselves can not ensure that they can continue to succeed. Innovative products and business capabilities are equally important, but not all enterprises have these two capabilities.

Bayer has a clear development strategy in China. We hope to make full use of our own scale advantages and achieve success through close cooperation with all sides and our global R & D and production capacity. Since 2017, Bayer has brought 14 innovative medicines and new indications to China, and will continue to bring a variety of innovative drugs to China to meet the medical needs of patients.

In terms of R & D, Bayer insists on making effective innovation through the combination of internal and external strategies. As an important component of China's innovation strategy, Bayer prescription medicine is accelerating the introduction of more innovative products into China through the global R & D network, especially in the field of cancer and cardiovascular diseases.

In addition, Bayer is also actively exploring cooperation with pharmaceutical companies at home and abroad, making use of complementary advantages to achieve win-win situation. For example, Bayer and cornerstone pharmaceutical are launching global clinical cooperation focusing on China. At present, the potential of combined therapy of bingo and PD-L1 monoclonal antibody for multiple types of tumors is being evaluated in order to develop better treatment options for patients.

For the current anti epidemic work, because of the lack of effective treatment options, it is urgent to find a new treatment for the new crown virus. As one of Bayer's global research projects, we have collaborated with the Canadian population health research institute to explore the treatment of the new crown virus. We look forward to contributing to the global fight against the new crown by working with all sides.

The impact of the epidemic on Bayer operation is limited.

Twenty-first Century: how does Bayer operate in China? Has it returned to normal?

Jiang Wei: at present, the national epidemic prevention and control has made significant strategic achievements. During the epidemic prevention and control, Bayer has been active in protecting the safety of employees and ensuring that the production and supply chain is not affected by the epidemic, and has taken all measures to make contributions to the national and the whole society's anti epidemic actions.

Bayer's 9000 employees in China are now safe and healthy. Bayer's factories and production bases in the whole country have been well operated except for a slight impact on the initial stage of the epidemic. Our resumption and resumption of production are all normal and orderly. Most factories are functioning normally during the epidemic and during the Spring Festival.

The group's sales grew by 6% in the first quarter of this year to 12 billion 800 million euros, of which the sales of prescription drug business increased by nearly 4% to 4 billion 500 million euros. The growth of crop science business and health consumer goods business is more obvious, reaching 5.7% and 13.5% respectively, which reflects Bayer's ability to successfully carry out business in a challenging environment.

Twenty-first Century: in your opinion, will people's attitude to health change after this epidemic?

Jiang Wei: the new crown virus epidemic makes people more aware of the importance of health. It also gives us greater confidence and determination, adhering to the vision of "sharing health and eliminating hunger", and using technology to make life healthier and better. Through this epidemic, people recognized the importance of improving their immunity and prevention.

Optimistic about China's development prospects

Twenty-first Century: how do you interpret the government work report of the two sessions this year? What are the opportunities or highlights for Bayer and multinational pharmaceutical companies?

Jiang Wei: this year's report on the work of the government is a summary of a special period of work and a forward-looking guidance for future work. There are not many words, but they are all dry goods, highlights and key points. My personal feeling is that the government always puts the economy, people's livelihood and the health and well-being of the masses in the first place, which is also very encouraging for the foreign enterprises that take root in China.

I also noted that in the eighth part, the state proposed strengthening the construction of public health system, insisting on the supremacy of life, reforming the disease prevention and control system, improving the direct reporting and early warning system of infectious diseases, increasing investment in research and development of vaccines, drugs and rapid detection technology, increasing epidemic prevention and treatment of medical facilities, strengthening grass-roots health and epidemic prevention, and carrying out patriotic health campaigns in depth. These are good information for our pharmaceutical enterprises, so that we can better integrate into the national public health system construction.

Bayer's vision of "sharing health and eliminating hunger" is highly consistent with China's current strategic development goals such as "healthy China" and "Rural Revitalization". The stable development of Chinese society provides a fundamental guarantee for Bayer's business activities in China. We believe that the long-term trend of China's economy will not change, and the potential and opportunities of the Chinese market will be enormous.

Twenty-first Century: in this year's government work report, we propose to create a fair and fair market environment for domestic and foreign capital enterprises. What do you think of it? What opportunities exist for multinational enterprises?

Jiang Wei: a fair and transparent business environment is the prerequisite for the continuous development of foreign-funded enterprises in China. As a long-term foreign-funded enterprise rooted in China, Bayer supports and appreciates the efforts made by the Chinese government to optimize the business environment. The new foreign investment law, which began in January this year, has emphasized the same treatment and fair treatment of domestic and foreign capital enterprises. This provides a clear legal basis for the further investment and development of our foreign-funded enterprises in the Chinese market. We expect that the foreign investment law and other relevant laws and regulations will be implemented everywhere at an early date to enhance the determination of foreign capital enterprises to enter China and long-term development in China.

Twenty-first Century: this year, the country mentioned the development of big health industry many times. In addition, this year is also the year for China to win the battle to build a well-off society in an all-round way and to fight a decisive battle against poverty. At the same time, it is the year when the 13th Five-Year plan was ended. Is this an opportunity for Bayer?

Jiang Wei: we believe that the importance of medical and agricultural development will continue in this year and in the future. Bayer will contribute to building a moderately prosperous society in China and tackling poverty by means of innovation and cooperation with the experience accumulated in China.

In the field of health care, we believe that the new crown pneumonia epidemic will accelerate the construction and improvement of China's public health system. We look forward to more policies to promote cooperation in medical innovation. Bayer will seize the rare development opportunities to accelerate the listing of various new drugs on the pipeline, so that more innovative products can benefit patients.

In terms of agriculture, Bayer will continue to respond to the call of the state, through our innovative advantages, to help build a well-off society in an all-round way. We will vigorously promote technological plant protection (plant protection) in the field of agriculture, unlock new skills to prevent diseases, pests, and weeds, and contribute to ensuring agricultural production, ensuring food security and increasing farmers' income.

Twenty-first Century: in general, how do you look at the Chinese economy and the global economy?

Jiang Wei: the impact of the new crown epidemic on the global economy is huge and far-reaching. At present, we can not predict the specific trend in the future. However, what we can see is that because of the decisive and effective epidemic prevention and control measures adopted by the government, and a series of targeted measures to protect people's livelihood and rehabilitation, China has not only taken the lead in achieving major achievements in the control of the epidemic, but also started to restart the economy, resumed work and resumed production, and gradually restored the people's life and economic operation to the right track. We have full confidence in China's economic prospects and prospects for China's development.

?